Download PDF
Semin Neurol 2022; 42(04): 503-511
DOI: 10.1055/a-1933-4366
Review Article

Preventive Treatment of Migraine

Candice M. Todd 
1   Department of Neurology, Centre for Headache, Women's College Hospital, University of Toronto, Toronto, Canada
,
Claire H. Sandoe
1   Department of Neurology, Centre for Headache, Women's College Hospital, University of Toronto, Toronto, Canada
,
Christine Lay
1   Department of Neurology, Centre for Headache, Women's College Hospital, University of Toronto, Toronto, Canada
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Migraine significantly impacts individuals from all walks of life and from all around the globe. Chronic or high-frequency episodic migraine has similar disability and burden on the healthcare system and can be challenging to manage. The focus of this article is to provide an outline of the available pharmacological and nonpharmacological evidence-based strategies that clinicians can employ to build a “toolbox” for their patients.

Keywords

migraine - prevention - prophylaxis - chronic headache


Publication History

Accepted Manuscript online:
30 August 2022

Article published online:
11 October 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Rasmussen BK. Epidemiology of headache. Cephalalgia 2001; 21 (07) 774-777
    CrossrefPubMedGoogle Scholar
  • 2 Dodick DW, Loder EW, Manack Adams A. et al. Assessing barriers to chronic migraine consultation, diagnosis, and treatment: results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study. Headache 2016; 56 (05) 821-834
    CrossrefPubMedGoogle Scholar
  • 3 Buse DC, Reed ML, Fanning KM, Bostic RC, Lipton RB. Demographics, headache features, and comorbidity profiles in relation to headache frequency in people with migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study. [published online ahead of print, October 14, 2020] Headache 2020; DOI: 10.1111/head.13966.
    CrossrefPubMedGoogle Scholar
  • 4 Lipton RB, Manack Adams A, Buse DC, Fanning KM, Reed ML. A comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: demographics and headache-related disability. Headache 2016; 56 (08) 1280-1289
    CrossrefPubMedGoogle Scholar
  • 5 Ishii R, Schwedt TJ, Dumkrieger G. et al. Chronic versus episodic migraine: the 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency. Headache 2021; 61 (07) 992-1003
    CrossrefPubMedGoogle Scholar
  • 6 Ailani J, Burch RC, Robbins MS. Board of Directors of the American Headache Society. The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache 2021; 61 (07) 1021-1039
    CrossrefPubMedGoogle Scholar
  • 7 Hepp Z, Dodick DW, Varon SF. et al. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia 2017; 37 (05) 470-485
    CrossrefPubMedGoogle Scholar
  • 8 Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012; 78 (17) 1337-1345
    CrossrefPubMedGoogle Scholar
  • 9 Goadsby PJ, Lipton RB, Ferrari MD. Migraine – current understanding and treatment. N Engl J Med 2002; 346 (04) 257-270
    CrossrefPubMedGoogle Scholar
  • 10 Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002; 288 (03) 351-357
    CrossrefPubMedGoogle Scholar
  • 11 Holroyd KA, Penzien DB, Cordingley GE. Propranolol in the management of recurrent migraine: a meta-analytic review. Headache 1991; 31 (05) 333-340
    CrossrefPubMedGoogle Scholar
  • 12 Stellar S, Ahrens SP, Meibohm AR, Reines SA. Migraine prevention with timolol. A double-blind crossover study. JAMA 1984; 252 (18) 2576-2580
    CrossrefPubMedGoogle Scholar
  • 13 Smith HS, Pappagallo M, Stahl SM. Essential Pain Pharmacology: The Prescriber's Guide. Timolol. Cambridge: Cambridge University Press; 2012: 454-456
    CrossrefGoogle Scholar
  • 14 Olerud B, Gustavsson CL, Furberg B. Nadolol and propranolol in migraine management. Headache 1986; 26 (10) 490-493
    CrossrefPubMedGoogle Scholar
  • 15 Dodick DW, Freitag F, Banks J. et al; CAPSS-277 Investigator Group. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther 2009; 31 (03) 542-559
    CrossrefPubMedGoogle Scholar
  • 16 By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2019; 67 (04) 674-694
    CrossrefPubMedGoogle Scholar
  • 17 Richardson K, Fox C, Maidment I. et al. Anticholinergic drugs and risk of dementia: case-control study. BMJ 2019; 367: l6213
    PubMedGoogle Scholar
  • 18 Loder E, Rizzoli P. Pharmacologic prevention of migraine: a narrative review of the state of the art in 2018. Headache 2018; 58 (Suppl. 03) 218-229
    CrossrefPubMedGoogle Scholar
  • 19 Ozyalcin SN, Talu GK, Kiziltan E, Yucel B, Ertas M, Disci R. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 2005; 45 (02) 144-152
    CrossrefPubMedGoogle Scholar
  • 20 Bulut S, Berilgen MS, Baran A, Tekatas A, Atmaca M, Mungen B. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin Neurol Neurosurg 2004; 107 (01) 44-48
    CrossrefPubMedGoogle Scholar
  • 21 Burch R. Antidepressants for preventive treatment of migraine. Curr Treat Options Neurol 2019; 21 (04) 18
    CrossrefPubMedGoogle Scholar
  • 22 Ha H, Gonzalez A. Migraine headache prophylaxis. Am Fam Physician 2019; 99 (01) 17-24
    PubMedGoogle Scholar
  • 23 Silberstein SD, Lipton RB, Dodick DW. et al; Topiramate Chronic Migraine Study Group. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 2007; 47 (02) 170-180
    CrossrefPubMedGoogle Scholar
  • 24 Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ. TOPMAT-MIG-201(TOP-CHROME) Study Group. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2007; 27 (07) 814-823
    CrossrefPubMedGoogle Scholar
  • 25 Silvestrini M, Bartolini M, Coccia M, Baruffaldi R, Taffi R, Provinciali L. Topiramate in the treatment of chronic migraine. Cephalalgia 2003; 23 (08) 820-824
    CrossrefPubMedGoogle Scholar
  • 26 Silberstein SD. Preventive migraine treatment. Continuum (Minneap Minn) 2015; 21 (4 Headache): 973-989
    CrossrefPubMedGoogle Scholar
  • 27 Quan A. Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. Early Hum Dev 2006; 82 (01) 23-28
    CrossrefPubMedGoogle Scholar
  • 28 Schuh-Hofer S, Flach U, Meisel A, Israel H, Reuter U, Arnold G. Efficacy of lisinopril in migraine prophylaxis – an open label study. Eur J Neurol 2007; 14 (06) 701-703
    CrossrefPubMedGoogle Scholar
  • 29 Bullo M, Tschumi S, Bucher BS, Bianchetti MG, Simonetti GD. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension 2012; 60 (02) 444-450
    CrossrefPubMedGoogle Scholar
  • 30 Tuchman MM, Hee A, Emeribe U, Silberstein S. Oral zolmitriptan in the short-term prevention of menstrual migraine: a randomized, placebo-controlled study. CNS Drugs 2008; 22 (10) 877-886
    CrossrefPubMedGoogle Scholar
  • 31 Maasumi K, Tepper SJ, Kriegler JS. Menstrual migraine and treatment options: review. Headache 2017; 57 (02) 194-208
    CrossrefPubMedGoogle Scholar
  • 32 Martinelli D, Arceri S, De Icco R. et al. BoNT-A efficacy in high frequency migraine: an open label, single arm, exploratory study applying the PREEMPT paradigm. Cephalalgia 2022; 42 (02) 170-175
    CrossrefPubMedGoogle Scholar
  • 33 Begasse de Dhaem O, Gharedaghi MH, Rizzoli P. Modifications to the PREEMPT protocol for onabotulinumtoxinA injections for chronic migraine in clinical practice. Headache 2020; 60 (07) 1365-1375
    CrossrefPubMedGoogle Scholar
  • 34 Diener HC. CGRP-targeted drugs for migraine: still many uncertainties. Lancet Neurol 2022; 21 (03) 209-210
    CrossrefPubMedGoogle Scholar
  • 35 Tepper SJ, Sheikh HU, Dougherty CO. et al. Erenumab dosage for migraine prevention: an evidence-based narrative review with recommendations. Headache 2022; 62 (04) 420-435
    CrossrefPubMedGoogle Scholar
  • 36 Tepper SJ, Lucas S, Ashina M. et al. Temporal response patterns to erenumab in patients with chronic migraine. Cephalalgia 2019; 39 (01) 211-212
    PubMedGoogle Scholar
  • 37 Barbanti P, Aurilia C, Cevoli S. et al; EARLY Study Group. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study. Headache 2021; 61 (09) 1351-1363
    CrossrefPubMedGoogle Scholar
  • 38 Dodick DW, Tepper SJ, Ailani J. et al. Risk of hypertension in erenumab-treated patients with migraine: analyses of clinical trial and postmarketing data. Headache 2021; 61 (09) 1411-1420
    CrossrefPubMedGoogle Scholar
  • 39 Sessa M, Andersen M. New insight on the safety of erenumab: an analysis of spontaneous reports of adverse events recorded in the US Food and Drug Administration Adverse Event Reporting System Database. BioDrugs 2021; 35 (02) 215-227
    CrossrefPubMedGoogle Scholar
  • 40 McAllister P, Lamerato L, Krasenbaum LJ. et al. Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States. J Headache Pain 2021; 22 (01) 156
    CrossrefPubMedGoogle Scholar
  • 41 Silberstein SD, Dodick DW, Bigal ME. et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 2017; 377 (22) 2113-2122
    CrossrefPubMedGoogle Scholar
  • 42 Pellesi L, De Icco R, Al-Karagholi MA, Ashina M. Reducing episodic cluster headaches: focus on galcanezumab. J Pain Res 2020; 13: 1591-1599
    CrossrefPubMedGoogle Scholar
  • 43 Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology 2018; 91 (24) e2211-e2221
    CrossrefPubMedGoogle Scholar
  • 44 Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 Randomized Clinical Trial. JAMA Neurol 2018; 75 (09) 1080-1088
    CrossrefPubMedGoogle Scholar
  • 45 Ashina M, Saper J, Cady R. et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 2020; 40 (03) 241-254
    CrossrefPubMedGoogle Scholar
  • 46 Dodick DW, Lipton RB, Silberstein S. et al. Eptinezumab for prevention of chronic migraine: a randomized phase 2b clinical trial. Cephalalgia 2019; 39 (09) 1075-1085
    CrossrefPubMedGoogle Scholar
  • 47 Lipton RB, Goadsby PJ, Smith J. et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology 2020; 94 (13) e1365-e1377
    CrossrefPubMedGoogle Scholar
  • 48 Silberstein S, Diamond M, Hindiyeh NA. et al. Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study. J Headache Pain 2020; 21 (01) 120
    CrossrefPubMedGoogle Scholar
  • 49 Martin V, Tassorelli C, Ettrup A, Hirman J, Cady R. Eptinezumab for migraine prevention in patients 50 years or older. Acta Neurol Scand 2022; 145 (06) 698-705
    CrossrefPubMedGoogle Scholar
  • 50 Winner PK, McAllister P, Chakhava G. et al. Effects of intravenous eptinezumab vs placebo on headache pain and most bothersome symptom when initiated during a migraine attack: a randomized clinical trial. JAMA 2021; 325 (23) 2348-2356
    CrossrefPubMedGoogle Scholar
  • 51 Edvinsson L. Oral rimegepant for migraine prevention. Lancet 2021; 397 (10268): 4-5
    CrossrefPubMedGoogle Scholar
  • 52 Croop R, Lipton RB, Kudrow D. et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet 2021; 397 (10268): 51-60
    CrossrefPubMedGoogle Scholar
  • 53 Singh A, Balasundaram MK. Atogepant for migraine prevention: a systematic review of efficacy and safety. Clin Drug Investig 2022; 42 (04) 301-308
    CrossrefPubMedGoogle Scholar
  • 54 Toni T, Tamanaha R, Newman B. et al. Effectiveness of dual migraine therapy with CGRP inhibitors and onabotulinumtoxinA injections: case series. Neurol Sci 2021; 42 (12) 5373-5376
    CrossrefPubMedGoogle Scholar
  • 55 Pellesi L, Do TP, Ashina H, Ashina M, Burstein R. Dual therapy with anti-CGRP monoclonal antibodies and botulinum toxin for migraine prevention: Is there a rationale?. Headache 2020; 60 (06) 1056-1065
    CrossrefPubMedGoogle Scholar
  • 56 Cohen F, Armand C, Lipton RB, Vollbracht S. Efficacy and tolerability of calcitonin gene-related peptide-targeted monoclonal antibody medications as add-on therapy to OnabotulinumtoxinA in patients with chronic migraine. Pain Med 2021; 22 (08) 1857-1863
    CrossrefPubMedGoogle Scholar
  • 57 Seng EK, Gosnell I, Sutton L, Grinberg AS. Behavioral management of episodic migraine: maintaining a healthy consistent lifestyle. Curr Pain Headache Rep 2022; 26 (03) 247-252
    CrossrefPubMedGoogle Scholar
  • 58 Evcili G, Utku U, Öğün MN, Özdemir G. Early and long period follow-up results of low glycemic index diet for migraine prophylaxis. Agri 2018; 30 (01) 8-11
    PubMedGoogle Scholar
  • 59 Ferrara LA, Pacioni D, Di Fronzo V. et al. Low-lipid diet reduces frequency and severity of acute migraine attacks. Nutr Metab Cardiovasc Dis 2015; 25 (04) 370-375
    CrossrefPubMedGoogle Scholar
  • 60 Turner DP, Lebowitz AD, Chtay I, Houle TT. Headache triggers as surprise. Headache 2019; 59 (04) 495-508
    CrossrefPubMedGoogle Scholar
  • 61 Kumar A, Bhatia R, Sharma G. et al. Effect of yoga as add-on therapy in migraine (CONTAIN): a randomized clinical trial. Neurology 2020; 94 (21) e2203-e2212
    CrossrefPubMedGoogle Scholar
  • 62 Smitherman TA, Kuka AJ, Calhoun AH. et al. Cognitive-behavioral therapy for insomnia to reduce chronic migraine: a sequential Bayesian analysis. Headache 2018; 58 (07) 1052-1059
    CrossrefPubMedGoogle Scholar
  • 63 Creswell JD, Lindsay EK, Villalba DK, Chin B. Mindfulness training and physical health: mechanisms and outcomes. Psychosom Med 2019; 81 (03) 224-232
    CrossrefPubMedGoogle Scholar
  • 64 Simshäuser K, Lüking M, Kaube H, Schultz C, Schmidt S. Is mindfulness-based stress reduction a promising and feasible intervention for patients suffering from migraine? A randomized controlled pilot trial. Complement Med Res 2020; 27 (01) 19-30
    CrossrefPubMedGoogle Scholar
  • 65 Seminowicz DA, Burrowes SAB, Kearson A. et al. Enhanced mindfulness-based stress reduction in episodic migraine: a randomized clinical trial with magnetic resonance imaging outcomes. Pain 2020; 161 (08) 1837-1846
    CrossrefPubMedGoogle Scholar
  • 66 Lagman-Bartolome AM, Lawler V, Lay C. Headache education active-waiting directive: a program to enhance well-being during long referral wait times. Headache 2018; 58 (01) 109-117
    CrossrefPubMedGoogle Scholar
  • 67 Schoenen J, Vandersmissen B, Jeangette S. et al. Prevention of migraine by supraorbital transcutaneous neurostimulation using the Cefaly® device (PREMICE): a multi-centre, randomized, sham-controlled trial. J Headache Pain 2013; 14 (Suppl 1): Epub 2013 Feb 21. PMCID: PMC3620126 184 DOI: 10.1186/1129-2377-14-S1-P184.
    CrossrefPubMedGoogle Scholar
  • 68 Starling AJ, Tepper SJ, Marmura MJ. et al. A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study). Cephalalgia 2018; 38 (06) 1038-1048
    CrossrefPubMedGoogle Scholar
  • 69 Schoenen J, Ambrosini A. Update on noninvasive neuromodulation for migraine treatment - vagus nerve stimulation. Prog Brain Res 2020; 255: 249-274
    CrossrefPubMedGoogle Scholar
  • 70 Diener HC, Goadsby PJ, Ashina M. et al. Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: the multicentre, double-blind, randomised, sham-controlled PREMIUM trial. Cephalalgia 2019; 39 (12) 1475-1487
    CrossrefPubMedGoogle Scholar
  • 71 Coppola G, De Pasqua V, Pierelli F, Schoenen J. Effects of repetitive transcranial magnetic stimulation on somatosensory evoked potentials and high frequency oscillations in migraine. Cephalalgia 2012; 32 (09) 700-709
    CrossrefPubMedGoogle Scholar
  • 72 Nowaczewska M, Wiciński M, Osiński S, Kaźmierczak H. The role of vitamin D in primary headache - from potential mechanism to treatment. Nutrients 2020; 12 (01) 243
    CrossrefPubMedGoogle Scholar
  • 73 von Luckner A, Riederer F. Magnesium in migraine prophylaxis - Is there an evidence-based rationale? A systematic review. Headache 2018; 58 (02) 199-209
    CrossrefPubMedGoogle Scholar
  • 74 Peikert A, Wilimzig C, Köhne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 1996; 16 (04) 257-263
    CrossrefPubMedGoogle Scholar
  • 75 Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E. Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012; 78 (17) 1346-1353
    CrossrefPubMedGoogle Scholar
  • 76 Maizels M, Blumenfeld A, Burchette R. A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. Headache 2004; 44 (09) 885-890
    CrossrefPubMedGoogle Scholar
  • 77 Wells RE, Baute V, Wahbeh H. Complementary and integrative medicine for neurologic conditions. Med Clin North Am 2017; 101 (05) 881-893
    CrossrefPubMedGoogle Scholar
  • 78 Pfaffenrath V, Diener HC, Fischer M, Friede M, Henneicke-von Zepelin HH. Investigators. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis – a double-blind, multicentre, randomized placebo-controlled dose-response study. Cephalalgia 2002; 22 (07) 523-532
    CrossrefPubMedGoogle Scholar
  • 79 Lösche W, Mazurov AV, Heptinstall S, Groenewegen WA, Repin VS, Till U. An extract of feverfew inhibits interactions of human platelets with collagen substrates. Thromb Res 1987; 48 (05) 511-518
    CrossrefPubMedGoogle Scholar
  • 80 Parohan M, Sarraf P, Javanbakht MH, Ranji-Burachaloo S, Djalali M. Effect of coenzyme Q10 supplementation on clinical features of migraine: a systematic review and dose-response meta-analysis of randomized controlled trials. Nutr Neurosci 2020; 23 (11) 868-875
    CrossrefPubMedGoogle Scholar
  • 81 Lipton RB, Göbel H, Einhäupl KM, Wilks K, Mauskop A. Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology 2004; 63 (12) 2240-2244
    CrossrefPubMedGoogle Scholar
  • 82 Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache 2007; 47 (03) 355-363
    PubMedGoogle Scholar